(S (NP (NP (NNS Studies)) (VP (VBG combining) (NP (NN psychotherapy)) (PP (IN with) (NP (NP (JJ psychedelic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP PsiDs)) (-RRB- -RRB-)))))) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (JJ positive) (NNS outcomes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB often)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP PsiDs) (POS ›)) (NN ability) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ 'mystical-type) ('' ›) (NNS experiences)) (PRN (-LRB- -LRB-) (NP (NNP MTEs)) (-RRB- -RRB-)) (: -) (NN i.e.) (, ,) (NP (NP (JJ subjective) (NNS experiences)) (SBAR (WHNP (WP$ whose) (NNS characteristics)) (S (VP (VBP include) (NP (NP (DT a) (NN sense)) (PP (IN of) (NP (NN connectedness) (, ,) (NN transcendence) (, ,) (CC and) (NN ineffability))))))))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT both) (NP (NNP PsiDs)) (CC and) (NP (JJ virtual) (NN reality))) (VP (MD can) (VP (VB be) (VP (VBN situated) (PP (IN on) (NP (NP (DT a) (JJR broader) (NN spectrum)) (PP (IN of) (NP (JJ psychedelic) (NNS technologies))))))))))) (. .))
(S (S (VP (TO To) (VP (VB test) (NP (DT this) (NN hypothesis))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NNS concepts)) (, ,) (NP (NNS methods)) (, ,) (CC and) (NP (NN analysis) (NNS strategies))) (PP (IN from) (NP (NNP PsiD) (NN research)))) (S (VP (TO to) (VP (VB design) (CC and) (VB evaluate) (NP (NN 'Isness) ('' ›) (, ,) (NP (NP (DT a) (JJ multi-person) (NNP VR) (NN journey)) (SBAR (WHADVP (WRB where)) (S (NP (NNS participants)) (VP (VB experience) (NP (NP (DT the) (JJ collective) (NN emergence) (, ,) (NN fluctuation) (, ,) (CC and) (NN dissipation)) (PP (IN of) (NP (PRP$ their) (NNS bodies)))) (PP (IN as) (NP (JJ energetic) (NNS essences)))))))))))) (. .))
(S (NP (NP (DT A) (NN study)) (PRN (-LRB- -LRB-) (NP (NNP N=57)) (-RRB- -RRB-)) (VP (VBG analyzing) (NP (NP (JJ participant) (NNS responses)) (PP (TO to) (NP (NP (DT a) (ADJP (RB commonly) (JJ used)) (NNP PsiD) (NN experience) (NN questionnaire)) (PRN (-LRB- -LRB-) (NP (NNP MEQ30)) (-RRB- -RRB-))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NNP Isness) (NNS participants)) (VP (VBD had) (NP (NP (NNP MTEs)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (VP (VBN reported) (PP (IN in) (NP (JJ double-blind) (JJ clinical) (NNS studies))) (PP (IN after) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN psilocybin) (CC &) (NNP LSD)))))))))))))) (. .))
(S (PP (IN Within) (NP (DT a) (NX (NX (JJ supportive) (NX (NN setting))) (CC and) (NX (JJ conceptual) (NN framework))))) (, ,) (NP (NNP VR) (NN phenomenology)) (VP (MD can) (VP (VB create) (NP (NP (DT the) (NNS conditions)) (PP (IN for) (NP (NNP MTEs))) (SBAR (WHPP (IN from) (WHNP (WDT which))) (S (NP (NNS participants)) (VP (JJ derive) (NP (NN insight) (CC and) (NN meaning)))))))) (. .))
